Multiple Myeloma: Updates on Diagnosis and Management

Overview

Journal Fed Pract

Specialty Health Services

Date 2019 Feb 16

PMID 30766130

Citations 6

Authors

Sarah Jewell

Zhifu Xiang

Anuradha Kunthur

Paulette Mehta

Affiliations

Soon will be listed here.

Abstract

Two- and 3-drug treatment regimens and autologous stem cell transplants provide opportunities for longer term disease remission, though most patients will still develop relapsed multiple myeloma.

Citing Articles

Correlation between melphalan chemotherapy with longitudinal global strain indices of the left ventricle in multiple myeloma patients: A velocity vector imaging (VVI) echocardiography study.

Mirsafaee L, Dehghani Firouzabadi M, Parkhideh S, Vahidnezhad H, Dehghani Firouzabadi F, Arab M Caspian J Intern Med. 2024; 15(1):199-201.

PMID: 38463920 PMC: 10921099. DOI: 10.22088/cjim.15.1.25.

Advancements on the Multifaceted Roles of Sphingolipids in Hematological Malignancies.

Raza Y, Atallah J, Luberto C Int J Mol Sci. 2022; 23(21).

PMID: 36361536 PMC: 9654982. DOI: 10.3390/ijms232112745.

Novel Psychoactive Substances: The Razor's Edge between Therapeutical Potential and Psychoactive Recreational Misuse.

Correia B, Fernandes J, Botica M, Ferreira C, Quintas A Medicines (Basel). 2022; 9(3).

PMID: 35323718 PMC: 8950629. DOI: 10.3390/medicines9030019.

Extramedullary Multiple Myeloma with Hepatic Involvement.

Singh M, Singh H, Pham P, Rizvi B, Rao R Cureus. 2021; 13(2):e13515.

PMID: 33786223 PMC: 7993922. DOI: 10.7759/cureus.13515.

"Please Keep Mom Alive One More Day"-Clashing Directives of a Dying Patient and Her Surrogate.

Latcha S, Lineberry C, Lendvai N, Tran C, Matsoukas K, Scharf A J Pain Symptom Manage. 2020; 59(5):1147-1152.

PMID: 32014529 PMC: 7531567. DOI: 10.1016/j.jpainsymman.2020.01.014.

References

Kumar S, Lee J, Lahuerta J, MORGAN G, Richardson P, Crowley J . Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2011; 26(1):149-57. PMC: 4109061. DOI: 10.1038/leu.2011.196. View

Kyle R, Remstein E, Therneau T, Dispenzieri A, Kurtin P, Hodnefield J . Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007; 356(25):2582-90. DOI: 10.1056/NEJMoa070389. View

Greipp P, San Miguel J, Durie B, Crowley J, Barlogie B, Blade J . International staging system for multiple myeloma. J Clin Oncol. 2005; 23(15):3412-20. DOI: 10.1200/JCO.2005.04.242. View

Siegel D, Martin T, Wang M, Vij R, Jakubowiak A, Lonial S . A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012; 120(14):2817-25. PMC: 4123387. DOI: 10.1182/blood-2012-05-425934. View

Rajkumar S, Dimopoulos M, Palumbo A, Blade J, Merlini G, Mateos M . International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014; 15(12):e538-48. DOI: 10.1016/S1470-2045(14)70442-5. View

Spencer A, Prince H, Roberts A, Prosser I, Bradstock K, Coyle L . Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol. 2009; 27(11):1788-93. DOI: 10.1200/JCO.2008.18.8573. View

Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M . Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011; 12(5):431-40. DOI: 10.1016/S1470-2045(11)70081-X. View

Haessler J, Shaughnessy Jr J, Zhan F, Crowley J, Epstein J, van Rhee F . Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clin Cancer Res. 2007; 13(23):7073-9. DOI: 10.1158/1078-0432.CCR-07-0527. View

Kumar S, Dispenzieri A, Lacy M, Hayman S, Buadi F, Gastineau D . Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia. 2007; 21(9):2035-42. DOI: 10.1038/sj.leu.2404801. View

10.

Pineda-Roman M, Zangari M, Haessler J, Anaissie E, Tricot G, van Rhee F . Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol. 2008; 140(6):625-34. PMC: 3655432. DOI: 10.1111/j.1365-2141.2007.06921.x. View

11.

Mateos M, Hernandez M, Giraldo P, Rubia J, de Arriba F, Lopez Corral L . Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med. 2013; 369(5):438-47. DOI: 10.1056/NEJMoa1300439. View

12.

Gay F, Hayman S, Lacy M, Buadi F, Gertz M, Kumar S . Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood. 2009; 115(7):1343-50. PMC: 2826759. DOI: 10.1182/blood-2009-08-239046. View

13.

Hulin C, Facon T, Rodon P, Pegourie B, Benboubker L, Doyen C . Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol. 2009; 27(22):3664-70. DOI: 10.1200/JCO.2008.21.0948. View

14.

Kyle R, Gertz M, Witzig T, Lust J, Lacy M, Dispenzieri A . Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003; 78(1):21-33. DOI: 10.4065/78.1.21. View

15.

Attal M, Harousseau J, Stoppa A, Sotto J, Fuzibet J, Rossi J . A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med. 1996; 335(2):91-7. DOI: 10.1056/NEJM199607113350204. View

16.

Moreau P, Avet-Loiseau H, Facon T, Attal M, Tiab M, Hulin C . Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood. 2011; 118(22):5752-8. DOI: 10.1182/blood-2011-05-355081. View

17.

Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T . Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012; 366(19):1782-91. DOI: 10.1056/NEJMoa1114138. View

18.

Landgren O, Kyle R, Pfeiffer R, Katzmann J, Caporaso N, Hayes R . Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009; 113(22):5412-7. PMC: 2689042. DOI: 10.1182/blood-2008-12-194241. View

19.

Palumbo A, Cavallo F, Gay F, Di Raimondo F, Yehuda D, Petrucci M . Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014; 371(10):895-905. DOI: 10.1056/NEJMoa1402888. View

20.

Richardson P, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T . Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005; 352(24):2487-98. DOI: 10.1056/NEJMoa043445. View